[Management of phosphate in chronic kidney disease--Phosphorus control by hemodialysis with long treatment time].
Hyperphosphatemia is an almost universal finding in patients with end-stage renal disease and is associated with increased all-cause mortality, cardiovascular mortality, and vascular calcification. Although new phosphate binders lead to a easy control of serum phosphorus levels, treatment time of a dialysis session might be the most important factor for controlling hyperphosphatemia. Two alternatives to conventional thrice weekly dialysis (CHD) are nocturnal hemodialysis (NHD) and short daily hemodialysis (SDHD) . The total weekly phosphorus removal with NHD and SDHS is significantly greater than that removed by CHD and this is associated with a significantly lower average serum phosphorous.